EGFR Exon 20 Insertions
Continuing Education is no longer available for the webinar.
Description:
The epidermal growth factor receptor (EGFR) gene encodes a receptor tyrosine kinase. In NSCLC numerous hotspot mutations within the tyrosine kinase domain led to constitutive activation and oncogenesis. Unlike classical TKI sensitive mutations, exon 20 insertions (which account for ~5% of total) are resistant to 1st, 2nd and 3rd generation EGFR TKIs. However, newly approved targeted therapies options have recently become available and been shown to be effective therapeutic options when this variant type is present. The scientific background information, testing techniques, and clinical applications of this biomarker will be discussed.
Learning Objectives:
- Describe the molecular biology of EGFR exon 20 mutations.
- Identify technical challenges for the detection of EGFR exon 20 mutations.
- Explain the clinical relevance of EGFR exon 20 mutations.
 |
 |
|---|---|
|
Speaker:
Eric Vail, MD Cedars Sinai Medical Center |
Moderator:
Jennifer Bynum, MD |
Date Recorded: December 6, 2022
Duration: 1 Hour
- Click the "Register Now" Button
- Log in using your AMP credentials. If you do not have an AMP account, Create a FREE account.
- Click on "Complete Registration" button
- Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.
Continuing Education Credit Information
Continuing Education is no longer available for the webinar. Note: Join the AMP Family for discounted access to the most current educational resources!All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.
